Detection of contaminating tumor cells by RT-PCR in breast cancer patients
Referring to the recently published study by Battaglia et al 1 we would like to contribute to the discussion concerning the analysis of breast cancer cell contamination in bone marrow (BM) and peripheral blood stem cell (PBSC) harvests by means of RT-PCR-based assays. As we 2 and others 3, 4 have reported, and also in accordance with Battaglia's observations, 1 the main limitation of the widely employed method of RT-PCR for cytokeratin-19 (K-19) mRNA 5 is the high incidence of false positive results. However, there may be some differences in the actual rate of false positivity according to the source of cells used for RT-PCR, that progressively decreased from peripheral blood (PB) samples to BM, PBSC and immunoselected CD34 + cell preparations (Ref. 2; and personal unpublished results). These observations suggested that, while RT-PCR assay for K-19 may be considered reliable enough for PBSC and CD34
+ cell preparations, the results obtained when dealing with BM samples must be interpreted with caution. Therefore, we were prompted to search for different markers of breast cancer cell contamination by developing RT-PCR assays for other gene targets; to this end, we compared the specificities and sensitivities of nested RT-PCR assays for K-19 2 and maspin 6 mRNA, and single-round RT-PCR assays for estrogen receptor (ER) 7 and epithelial growth factor receptor (EGFR) 8 mRNA. We found that all four genes were expressed at high levels in fresh mammary tissues, either normal or neoplastic (n = 10 for both), and in the breast cancer cell line MCF-7. Of interest was the observation that all five neoplastic samples that were ER negative with conventional cell assays did indeed express ER mRNA, although with considerable quantitative differences, reflecting the heterogeneity of ER expression in breast cancer cells. 9 On the other hand, none of the purified CD34
+ cell suspensions (n = 14) prepared from patients with lymphomas or myelomas showed positivity for any of the genes examined. The incidence of false positive results in a total of 110 samples of BM (n = 65) and PBSC (n = 45) from healthy donors and patients with either neoplastic and non-neoplastic hematological diseases was as follows: 15% and 2.5% for K-19, 0% and 0% for maspin, 5% and 0% for ER, 1.5% and 0% for EGFR in BM and PBSC samples, respectively. Therefore, there was a definitely lower incidence of false positive results obtained using the other three assays as compared to K-19. Furthermore, the sensitivities of the four RT-PCR assays, calculated by using progressive dilutions of MCF-7 cells, was comparable (at the level of one tumor cell among 0.2-0.5 × 10 7 normal BM mononuclear cells). Based on these results, we then examined BM and PBSC samples obtained from 45 patients with high-risk, stage II/III, breast cancer enrolled in an autologous BM transplant program. First of all, we found that maspin assay failed to produce any positive results, even in BM samples that were highly contaminated with cancer cells (as detected by concurrent immunohistochemistry analysis-IHC; see Ref. 2 for details). This could be ascribed both to the much lower detection limit of maspin assay on fresh cancer cells (see below) and to the loss of maspin gene expression that has been shown to occur during tumor progression. 10 The other three assays produced different positivity rates, that are not reported in detail. However, when we compared the overall results of RT-PCR assays with those derived from IHC analysis, the higher degree of concordance between the two techniques was found for K-19 assay, while both ER and EGFR assays significantly underestimated cancer cell contamination. In fact, among the 25 patients who were positive by the K19 assay, BM cancer cell contamination was found also by IHC in 22 (89%); in contrast, of these only nine (36%) and 12 (49%) were also positive for ER and EGFR assays, respectively. The most likely explanation for these results is that the expression levels of these genes in fresh cancer tissues is different from MCF-7 cells. Indeed, we observed that sensitivity curves generated by progressive dilutions of fresh cancer cells (n = 5 experiments) were more than 20-fold lower for maspin (1 positive cell among 1-2.5 × 10 5 normal BM cells) and about two-to 10-fold lower for ER and EGFR (1 positive cell among 0.2-0.5 × 10 6 BM cells); on the other hand, the curve for K-19 was virtually superimposable on that of MCF-7 cells.
In conclusion, RT-PCR for K-19 mRNA still appears to be the most reliable assay in breast cancer patients; actually, an association of RT-PCR for K-19 and IHC analysis seems to be the recommended procedure for establishing cancer cell contamination in BM samples, while the higher specificity of the RT-PCR assay might be sufficient as a sole assay in the case of PBSC and CD34 + cell suspensions. Therefore, the improved one-step method described by Battaglia et al, 1 that has been shown to have comparable sensitivity to the conventional two-step procedure, might be of help in further increasing the specificity of the procedure.
A clinical correlation between tumor cell contamination of PBSC collections used for reinfusion and relapse-free survival after autologous transplantation has been shown in our previous study; 2 while those data await confirmation on larger patient populations, it seems appropriate to continue to search for methods which permit a more accurate selection of highrisk patients with limited disease at onset. This group of patients could indeed benefit from more intensive or alternative therapeutic regimens, including reinfusion with tumor-free cell products either by immunoselection of stem cells 2, [8] [9] [10] [11] or other innovative purging methodologies. The purpose of the present study was to assess the tumor cell content in peripheral blood stem cell (PBSC) harvests from patients with metastatic neuroblastoma before and after CD34 + cell enrichment in order to evaluate the efficacy of this procedure in terms of indirect tumor cell purging. Detection of contaminating neuroblasts was done using a combination of immunofluorescence assay (IFA) and RT-PCR method. A dual-color fluorochrome labelling with anti-neuroblastoma UJ-13-A and anti-panleucocyte CD45 antibodies, and RT-PCR amplification of tyrosine hydroxylase (TH) mRNA, a tissue-specific marker of neuroblasts, were performed in two different laboratories as already described. 2, 3 The sensitivity of neuroblastoma cell detection has been evaluated and reported to be of one malignant cell in 10 5 for IFA and one in 10 6 for RT-PCR. Equal-size samples (1-2 × 10 6 cells) from PBSC harvests of 13 neuroblastoma patients were analyzed by the two tests before and after CD34 selection ( Table 1 ). The patients (median age 3 years) had stage IV tumors with bone marrow metastases at diagnosis. At the time of harvesting, the patients were in medullary remission, as assessed by cyto-logical examination of 10 bone marrow aspirates and two core biopsies, but most of them had a bone disease detectable on meta-iodobenzylguanidine scans. CD34
+ cell selection was performed by an immunoabsorption method (CellPro, Bothell, WA, USA), and achieved a median purity of 73% (range 46-81%) CD34
+ cells. All samples of both unseparated and CD34 selected harvests were found to be negative by immunofluorescence analysis. In contrast, RT-PCR assay revealed the presence of tumor contamination in nine out of 13 (69%) whole leukapheresis products. After CD34 + cell selection, one of the nine (11%) grafts examined by RT-PCR showed detectable residual contamination.
The data from immunofluorescence and RT-PCR assays and the information on their sensitivity allowed us to estimate the intervals for the total number of malignant cells contained in PBSC harvests before and after CD34 + cell selection, using the approach proposed by Leung et al. 1 The intervals were calculated on the basis of malignant cell concentrations and total mononuclear cell counts, in whole and CD34 selected fractions. The frequency of tumor cells in the harvests was assumed to be between 1 in 10 5 cells and 1 in 10 6 cells if IFA was negative and RT-PCR was positive. In samples showing no detectable tumor cells by both tests, the tumor cell concentration was considered to be between 0 and 1 in 10 6 . For cases 10-13 in which no PCR data were available after selection, results of immunofluorescence analysis suggested that the residual tumor cell concentration in CD34 selected fractions would be between 0 and 1 in 10 5 . Knowing the absolute number of mononuclear cells in
